Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Benefit claimants, whistleblowers and welfare experts working on the frontline offer Labour ministers alternatives to cuts ...

The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...

The following is a summary of “Neurofilament heavy chain in secondary progressive multiple sclerosis,” published in the January 2025 issue of Neurology by Angelis et al. Biomarkers are essential for ...

Tiziana Life Science announced its intention not to engage in a capital raising activities for the immediate future. Following on from its news ...

RRMS may also progress to secondary progressive MS. SPMS follows an initial pattern of relapses and remissions and then gets progressively worse. RRMS can eventually transition to SPMS.

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

Frexalimab is under clinical development by Sanofi and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase III drugs for Secondary Progressive ...

Similarly, evobrutinib failed to show superiority in most secondary and tertiary outcomes ... be less effective in relapsing than in progressive disease. Trials including participants with progressive ...